NEW YORK (TheStreet) -- Geron (GERN) surged Thursday after the company announced the FDA had removed a partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST).
The FDA placed the hold in March 2014 because of safety concerns of hepatotoxicity in the clinical trials of imetelstat. The investigator, Dr. Ayalew Tefferi of the Mayo Clinic in Rochester, Minnesota, gave follow-up information on the reversibility of hepatotoxicity for all patients who received imetelstat in the trial, and the FDA informed him in a letter Wednesday that the trial could continue.
The stock was up 22.69% to $3.19 at 9:56 a.m. on Thursday.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV